Day: August 12, 2024

Crescent Capital BDC, Inc. Reports Second Quarter 2024 Earnings Results; Declares a Third Quarter Base Dividend of $0.42 Per Share, and a Second Quarter Supplemental Dividend of $0.09 Per Share

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

LOS ANGELES, Aug. 12, 2024 (GLOBE NEWSWIRE) — Crescent Capital BDC, Inc. (“Crescent BDC” or “Company”) (NASDAQ: CCAP) today reported net investment income of $0.59 per share and net income of $0.55 per share for the quarter ended June 30, 2024. Net asset value per share increased to $20.30 compared to $20.28 as of March 31, 2024. Dividend Declarations   The Company’s Board of Directors (the “Board”) declared a third quarter 2024 regular cash dividend of $0.42 per share to stockholders of record as of September 30, 2024, payable on October 15, 2024. The Board also announced a second quarter 2024 supplemental cash dividend of $0.09 per share to stockholders of record as of August 31, 2024, payable on September 16, 2024. Selected Financial Highlights($ in millions, except per share amounts)   As of and for the three months ended       June...

Continue reading

FreightCar America, Inc. Reports Second Quarter 2024 Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Company delivers 66% year-over-year revenue growth with record profitability at new plant, raises full year guidance Secured ~3,000 orders, including first tank car conversion order CHICAGO, Aug. 12, 2024 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a diversified manufacturer and supplier of railroad freight cars, railcar parts and components, today reported results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights Revenues of $147.4 million on 1,159 railcar deliveries, an increase of 66% compared to revenues of $88.6 million on 760 railcar deliveries in the second quarter of 2023 Gross margin of 12.5% with gross profit of $18.4 million, compared to gross margin of 14.6% with gross profit of $13.0 million in the second quarter of 2023 Net Income of...

Continue reading

Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan Company secures up to $16M funding from existing investors supported by BT-600 results and progress toward BioJet™ partnership Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the second quarter ended June 30, 2024. “Research shows that ulcerative colitis patients with higher drug exposure in the colon tissue have significantly better responses to therapy,” said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. “Our...

Continue reading

KULR Technology Group Reports Second Quarter 2024 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a global leader in sustainable energy management, today reported results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Results Revenues: In the second quarter that ended June 30, 2024, revenue was $2.43 million compared to $2.70 million reported in the same period last year. Contract Services revenue increased 75.7%, with revenue of approximately $1.30 million versus approximately $738 thousand in the same quarter last year. Cash and Accounts Receivable: As of June 30, 2024, the Company had cash and accounts receivable combined of $2.94 million. Gross Margins: Gross margin was 24% in the quarter ending June 30, 2024, compared to 37% in the same period last year. Selling,...

Continue reading

BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Company reports transformative second-quarter revenue, contributing to a record total of $116.4 million in revenue for the first half of 2024 AmnioWrap2 continues to be a major growth driver achieving an impressive 56.5% sequential revenue increase compared to Q1 2024 Achieves second consecutive quarter of positive net income with $6.3 million Generated Adjusted Q2 2024 EBITDA of $10.0 million Financial Results Conference Call and Webcast on Monday, August 12, 2024, at 4:30 pm EDT POMPANO BEACH, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics, reports financial results for the second quarter ended June 30, 2024. The Company will host a webcast and conference call on Monday, August...

Continue reading

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Completed enrollment of initial Cohort 2 patients in its VMT-α-NET and VMT01 clinical trials On track to advance multiple pre-IND assets into the clinic in the next 12-18 months Making continued progress on build out of manufacturing infrastructure Cash, cash equivalents and short-term investments balance of approximately $293 million expected to be sufficient to fund our current planned operations and capital investments into mid-2026 SEATTLE, Aug. 12, 2024 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced second quarter financial results for the period ended June 30, 2024. “The team has been steadfast in moving our two clinical programs towards...

Continue reading

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Enrollment ongoing in SZN-043 Phase 1b trial in patients with Severe Alcoholic Hepatitis Presented first-in-human data from SZN-043 Phase 1a trial at EASL Published study that demonstrated application of unique Targeted Protein Degradation technologies resulting in robust Wnt signal activation in bispecific antibodies based on the Company’s SWEETS technology platform SOUTH SAN FRANCISCO, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided second quarter 2024 financial results and business updates. “We made significant progress in the second quarter with accomplishment of key milestones including dosing the first patient in the SZN-043 Phase...

Continue reading

Spectral AI Announces 2024 Second Quarter Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Second Quarter Revenue Totals $7.5 Million Total Enrollment Exceeds 85% for Burn Center Pivotal U.S. Clinical Trial Q2 2024 Overview Research & Development Revenue of $7.5 Million Cash Position of $6.9 Million On Track to Generate First Commercial Revenues in the U.K. Later this Year Burn Pivotal Study Nearing Completion Paving the Way for U.S. FDA Submission in Early 2025 Announced Collaboration with PolyNovo Ltd. Providing Introduction to Australian Market Continued Progress in Handheld Burn Wound Diagnostic Technology Added to Russell Microcap® Index effective July 1, 2024 DALLAS, Aug. 12, 2024 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today...

Continue reading

Helius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Company to host call at 4:30pm today NEWTOWN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter ended June 30, 2024. Second Quarter and Recent Business Updates Secured the first third-party reimbursement for the Portable Neuromodulation Stimulator (“PoNS®”) device from a major insurance carrier at $23,900, representing a significant milestone toward increasing PoNS accessibility. Received preliminary Centers for Medicare & Medicaid Services (“CMS”) payment determination for reimbursement of PoNS, paving the way to final price determination on October 1, 2024. Completed site participation enrollment for...

Continue reading

SKYX Reports Record Second Quarter Sales of $21.4 Million Compared to $15.0 Million for Second Quarter 2023 as it Continues to Grow its Market Penetration in the U.S and Canada of its Advanced and Smart Platform Products

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

MIAMI, Aug. 12, 2024 (GLOBE NEWSWIRE) — SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the “Company” or “SKYX”), a highly disruptive platform technology company with over 97 pending and issued patents globally and over 60 lighting and home décor websites, with a mission to make homes and buildings become safe and smart as the new standard, today reported its financial and operational results for the second quarter ended June 30, 2024. Second Quarter 2024 and Recent Achievements Generated record second quarter revenues of $21.4 million compared to $15.0 million for the second quarter of 2023, including sales of its advanced and smart platform plug and play products. Reported $15.6 million in cash, cash equivalents, and restricted cash, as of June 30, 2024, as compared to $19.8 million as of March 31, 2024. As common...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.